A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

Nature Medicine

Volumn 11, Issue 5, 2005, Pages 551-555

  Tuszynski, Mark H ^a,b   Thal, Leon ^a,b   Pay, Mary ^a   Salmon, David P ^a   Sang U, Hoi ^c   Bakay, Roy ^d   Patel, Piyush ^e   Blesch, Armin ^a   Vahlsing, H Lee ^a,b   Ho, Gilbert ^a   Tong, Gang ^a   Potkin, Steven G ^f   Fallon, James ^f   Hansen, Lawrence ^a   Mufson, Elliott J ^d   Kordower, Jeffrey H ^d   Gall, Christine ^f   Conner, James ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e University of California at San Diego   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; NERVE GROWTH FACTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; FEMALE; FIBROBLAST; FOLLOW UP; GENE DELIVERY SYSTEM; GENE THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MINI MENTAL STATE EXAMINATION; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT;

AGED; ALZHEIMER DISEASE; CHOLINERGIC FIBERS; COGNITION; FIBROBLASTS; FLUORODEOXYGLUCOSE F18; GENE THERAPY; HISTOLOGICAL TECHNIQUES; HUMANS; MIDDLE AGED; NERVE GROWTH FACTOR; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PROSENCEPHALON;

ANIMALIA;

EID: 21044458854     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1239     Document Type: Article

References (35)

1. Hefti, F. Nerve growth factor (NGF) promotes survival of septal cholinergic neurons after fimbrial transection. J. Neurosci. 6, 2155-2162 (1986).
2. Fischer, W. et al. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329, 65-68 (1987).
3. Tuszynski, M.H., U, H.S., Amaral, D.G. & Gage, F.H. Nerve growth factor infusion in primate brain reduces lesion-induced cholinergic neuronal degeneration. J. Neurosci. 10, 3604-3614 (1990).
4. Emerich, D.W. et al. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: Rescue and sprouting of degenerating cholinergic basal forebrain neurons. J. Comp. Neurol. 349, 148-164 (1994).
5. Cooper, J.D. et al. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc. Natl. Acad. Sci. USA 98, 10439-10444 (2001).
6. Capsoni, S., Giannotta, S. & Cattaneo, A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. USA 99, 12432-12437 (2002).
7. Tuszynski, M.H. Gene therapy for neurodegenerative disorders. Lancet Neurol. 1, 51-57 (2002).
8. Levi-Montalcini, R. The nerve growth factor 35 years later. Science 237, 1154-1162 (1987).
9. Bartus, R., Dean, R.L., Beer, C. & Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-417 (1982).
10. Mesulam, M.M. & Geula, C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J. Comp. Neurol. 275, 216-240 (1988).
11. Kilgard, M.P. & Merzenich, M.M. Cortical map reorganization enabled by nucleus basalis activity. Science 279, 1714-1718 (1998).
12. Conner, J.M., Culberson, A., Packowski, C., Chiba, A., Tuszynski, M.H. Lesions of the basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity associated with motor skill learning. Neuron 38, 819-829 (2003).
13. Perry, E.K. et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Brit. Med. J. 2, 1457-1459 (1978).
14. Rosenberg, M.B. et al. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science 242, 1575-1578(1988).
15. Chen, K.S. & Gage, F.H. Somatic gene transfer of NGF to the aged brain: Behavioral and morphological amelioration. J. Neurosci. 15, 2819-2825 (1995).
16. Tuszynski, M.H., Roberts, J., Senut, M.C., U, H.-S. & Gage, F.H. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Therapy 3, 305-314 (1996).
17. Smith, D.E., Roberts, J., Gage, F.H., Tuszynski, M.H. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc. Nat. Acad. Sci. USA 96, 10893-10898 (1999).
18. Conner, J.M., Darracq, M.A., Roberts, J., Tuszynski, M.H. Non-tropic actions of neurotrophins: Subcortical NGP gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. Proc. Natl. Acad. Sci. USA 98, 1941-1946 (2001).
19. Tuszynski, M.H. & Gage, F.H. Bridging grafts and transient NGP infusions promote long-term CNS neuronal rescue and partial functional recovery. Proc. Natl. Acad. Sci. USA 92, 4621-4625 (1995).
20. Stern, R.G. et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am. J. Psychiatry 151, 390-396 (1994).
21. Thal, L.J. et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 61, 1498-1502 (2003).
22. Potkin, S.G. et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int. J. Neuropsychopharmacol. 4, 223-230 (2001).
23. Molinari, M., Filippini, V. & Leggio, M.G. Neuronal plasticity of interrelated cerebellar and cortical networks. Neuroscience 111, 863-870 (2002).
24. Gottwald, B., Mihajlovic, Z., Wilde, B. & Mehdorn, H.M. Does the cerebellum contribute to specific aspects of attention? Neuropsychologia 41, 1452-1460 (2003).
25. Lyons, K.E., Wilkinson, S.B., Overman, J. & Pahwa, R. Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Neurology 63, 612-616 (2004).
26. Eriksdotter Jonhagen, M. et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 9, 246-257 (1998).
27. Mayeux, R., Sano M. Treatment of Alzheimer's disease. N. Engl. J. Med. 341, 1670-1679 (1999).
28. Masliah, E. et al. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci. Lett. 174, 67-72 (1994).
29. Mesulam, M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn. Mem. 11, 43-49 (2004).
30. Selkoe, D.J. & Schenk, D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545-584 (2003).
31. Gill, S.S. et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9, 589-595 (2003).
32. Slevin, J.T., Gerhardt, G.A., Smith, C.D., Gash, D.M., Kryscio, R.J. & Young, A.B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 102, 216-222 (2005).
33. McKhann, G. et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944 (1984).
34. Lee, R., Kermani, P., Teng, K.K. & Hempstead, B.L. Regulation of cell survival by secreted proneurotrophins. Science 294, 1945-1948(2001).
35. Rosen, W.G., Mohs, R.C., et al. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 141, 1356-1364 (1984).